Avivagen Overview

  • Founded
  • 1997
Founded
  • Status
  • Public
  • Employees
  • 14
Employees
  • Stock Symbol
  • VIV
Stock Symbol
  • Investments
  • 3
  • Share Price
  • $0.41
  • (As of Friday Closing)

Avivagen General Information

Description

Avivagen Inc is a Canadian based company operating in the healthcare sector. It develops science-based, natural health products for animals. It develops and commercializes products for livestock feeds to replace antibiotics for growth promotion and to help prevent disease by supporting the animal's health defenses. The company's products are based on OxC-beta Technology. Its geographical segments include the Philippines, which is the key revenue driver; Mexico; Thailand; United States; Malaysia; Taiwan; Brazil; and others.

Contact Information

Formerly Known As
Occell, Chemaphor
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Food Products
Stock Exchange
TSX
Primary Office
  • 100 Sussex Drive
  • Ottawa, Ontario K1A 0R6
  • Canada
+1 (613) 000-0000

Avivagen Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Avivagen Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.41 $0.42 $0.30 - $0.61 $23M 56.8M 164K -$0.08

Avivagen Financials Summary

In Thousands,
USD
TTM 31-Jan-2021 FY 2020 31-Oct-2020 FY 2019 31-Oct-2019 FY 2018 31-Oct-2018
EV 22,655 16,002 13,897 15,661
Revenue 890 875 735 833
EBITDA (2,431) (2,539) (2,938) (3,697)
Net Income (3,499) (3,530) (3,638) (3,755)
Total Assets 1,115 1,633 1,434 2,370
Total Debt 5,260 4,601 3,484 1,717
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Avivagen Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Avivagen‘s full profile, request access.

Request a free trial

Avivagen Executive Team (4)

Name Title Board Seat Contact Info
Kym Anthony Chief Executive Officer & Board Member
Chris Boland Chief Financial Officer
Graham Burton Ph.D Chief Scientific Officer & Founder
You’re viewing 3 of 4 executive team members. Get the full list »

Avivagen Board Members (3)

Name Representing Role Since
000000 000 00 Self Board Member 000 0000
000 0000000 Avivagen Chief Executive Officer & Board Member 000 0000
0000 00000000 Avivagen Director 000 0000
To view Avivagen’s complete board members history, request access »

Avivagen Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Avivagen Investments & Acquisitions (3)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 00000 13-Jun-2019 00000 0000000 Other Consumer Non-Durables 000 0000000
0000000 000000 21-Jun-2010 000000000000000000 00000 Biotechnology
Triumph Acquisition Corporation 05-Aug-2005 Merger/Acquisition Holding Companies
To view Avivagen’s complete investments and acquisitions history, request access »